Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 31;18(1):2028513.
doi: 10.1080/21645515.2022.2028513. Epub 2022 Feb 1.

Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children

Affiliations

Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children

Weerawan Hattasingh et al. Hum Vaccin Immunother. .

Abstract

Japanese encephalitis is the main cause of viral encephalitis in Asia. In a previous single-arm vaccine trial, an inactivated chromatographically purified Japanese encephalitis Vero cell vaccine (CVI-JE; JEVACTM) was safe and immunogenic in 152 Thai children aged 1-3 years receiving a 2-dose primary immunization and booster dose 1 year later. We conducted a 5-year follow-up assessment of the persistence of the immune response the 144 children remaining in this cohort after first booster dose. Immunity was assessed by 50% plaque reduction neutralization test annually for up to 5 years post-booster. Seroprotection rates (95%CI) decreased from 100% (97.1-100) at 1 year post-booster to 93% (85.0-98.3) at 5 years post-booster. No serious vaccine-related adverse events or Japanese encephalitis infections were reported. A 2-dose primary immunization and booster 1 year later with CVI-JE provided long-lasting immunity in the majority of children.

Keywords: Children; Japanese encephalitis vaccine; chromatographical purify; immunogenicity; inactivated Vero cell-derived vaccine; long-term follow-up.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Disposition of participants.

References

    1. Pearce JC, Learoyd TP, Langendorf BJ, Logan JG.. Japanese encephalitis: the vectors, ecology and potential for expansion. J Travel Med. 2018;25(suppl_1):S16–6. doi: 10.1093/jtm/tay009. - DOI - PubMed
    1. Oliveira ARS, Cohnstaedt LW, Strathe E, Etcheverry L, McVey DS, Piaggio J, Cernicchiaro N.. Meta-analyses of Japanese encephalitis virus infection, dissemination, and transmission rates in vectors. Am J Trop Med Hyg. 2018;98(3):883–90. doi: 10.4269/ajtmh.17-0622. - DOI - PMC - PubMed
    1. Kumari R, Kumar K, Rawat A, Singh G, Yadav NK, Chauhan LS. First indigenous transmission of Japanese encephalitis in urban areas of National Capital Territory of Delhi, India. Trop Med Int Health. 2013;18(6):743–49. doi: 10.1111/tmi.12104. - DOI - PubMed
    1. Xu Y, Zhaori G, Vene S, Shen K, Zhou Y, Magnius LO, Wahren B, Linde A. Viral etiology of acute childhood encephalitis in Beijing diagnosed by analysis of single samples. Pediatr Infect Dis J. 1996;15(11):1018–24. doi: 10.1097/00006454-199611000-00017. - DOI - PubMed
    1. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89(10):766–74, 774A–774E. doi: 10.2471/BLT.10.085233. - DOI - PMC - PubMed

LinkOut - more resources